Mission Therapeutics receives major research grant from MJFF.
M2 EQUITYBITES-April 13, 2017-Mission Therapeutics receives major research grant from MJFF
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Mission Therapeutics has been presented with a grant from the Michael J. Fox Foundation for Parkinson's Disease (MJFF), the Manufacturing Chemist website reported on Thursday.
The company operates in drug discovery and development, with a focus on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with a high unmet medical need.
The grant from MFJJ will help to facilitate the testing of Mission Therapeutics' potent and selective USP30-targeted inhibitors in translationally relevant stem cell-derived Parkinson's disease models.
Professor Richard Wade-Martins developed the models with his research group at the University of Oxford.
Mission Therapeutics will study the inhibition of USP30 to determine whether this promotes mitophagy and, consequentially, improves cellular resilience in Parkinson's and other neurodegenerative diseases.
Parkinson's disease is a chronic, degenerative neurological disorder affecting one in 100 people over the age of 60. There is no objective test or biomarker for the disease, meaning the rate of misdiagnosis can be relatively high.
It also means that estimates of those living with Parkinson's vary -- though recent research suggests more than five million people worldwide have the disease.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Apr 13, 2017|
|Previous Article:||Kazakhstan pharmaceutical complex to become producer of cancer drugs.|
|Next Article:||Takeda and NuBiyota team up to develop microbial ecosystem therapeutic products for GI indications.|